W304409

L-(+)-Tartaric acid

≥99.7%, FCC, FG

• Synonym(s): (2R,3R)-(+)-Tartaric acid, L-Threaric acid
• Linear Formula: HO₂CCH(OH)CH(OH)CO₂H
• CAS Number: 87-69-4
• Molecular Weight: 150.09
• FEMA Number: 3044
• Council of Europe no.: 18
• UNSPSC Code: 12164502
• PubChem Substance ID: 24901442
• NACRES: NA.21
• EC Number: 201-766-0
• Flavis number: 8.018
• MDL number: MFCD00064207
• Beilstein/REAXYS Number: 1725147
• Organoleptic: odorless
• Grade: FG, Halal
• Biological source: synthetic
• Agency: meets purity specifications of JECFA
• Food allergen: no known allergens

Properties

• biological source: synthetic
• Quality Segment: 300, 400
• grade: FG, Halal
• agency: meets purity specifications of JECFA
• reg. compliance: EU Regulation 1334/2008 & 178/2002, FCC, FDA 21 CFR 163.110, FDA 21 CFR 163.111, FDA 21 CFR 163.112, FDA 21 CFR 184.1099
• vapor density: 5.18 (vs air)
• assay: ≥99.7%
• form: crystalline powder
• optical activity: [α]20/D +12.5°, c = 20 in H₂O
• autoignition temp.: 797 °F
• mp: 170-172 °C (lit.)
• solubility: water: soluble 150 g/L at 25 °C
• cation traces: As: ≤3 ppm, Cd: ≤1 ppm, Hg: ≤1 ppm, heavy metals (as Pb): ≤2 ppm
• application(s): flavors and fragrances
• documentation: see Safety & Documentation for available documents
• food allergen: no known allergens
• organoleptic: odorless
• SMILES string: O[C@H]([C@@H](O)C(O)=O)C(O)=O
• InChI: 1S/C4H6O6/c5-1(3(7)8)2(6)4(9)10/h1-2,5-6H,(H,7,8)(H,9,10)/t1-,2-/m1/s1
• InChI key: FEWJPZIEWOKRBE-JCYAYHJZSA-N

Description

General description

L-(+)-Tartaric acid is an organic acid commonly used as an acidulant, flavor enhancer, firming agent and humectant.

Application

• Terahertz-spectroscopy for non-destructive determination of crystallinity of L-tartaric acid in smartFilms and tablets made from paper.: This study leverages terahertz spectroscopy to assess the crystallinity of L-(+)-tartaric acid in innovative pharmaceutical applications, enhancing non-destructive testing methods for quality control (Ornik et al., 2020 May). Link to the article.


• Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations.: Research shows the use of L-(+)-tartaric acid in cocrystal formulations with itraconazole to improve its pulmonary absorption, demonstrating a significant advancement in drug delivery technologies (Karashima et al., 2017 Jun). Link to the article.


• Physicochemical Evaluation and Developability Assessment of Co-amorphouses of Low Soluble Drugs and Comparison to the Co-crystals.: This article discusses the role of L-(+)-tartaric acid in enhancing the solubility and bioavailability of pharmaceuticals through co-amorphous systems, offering a critical insight into drug formulation strategies (Yamamoto et al., 2016 Dec). Link to the article.


• Functionalized polycarbonate derived from tartaric acid: enzymatic ring-opening polymerization of a seven-membered cyclic carbonate.: This research explores the synthesis of biodegradable polymers from L-(+)-tartaric acid, emphasizing its utility in developing environmentally friendly materials (Wu et al., 2008 Oct). Link to the article.

Safety Information

• pictograms: GHS05
• signalword: Danger
• hcodes: H318
• pcodes: P280 - P305 + P351 + P338
• Hazard Classifications: Eye Dam. 1
• Storage Class: 11 - Combustible Solids
• flash_point_f: 302.0 °F - closed cup
• flash_point_c: 150 °C - closed cup
• ppe: dust mask type N95 (US), Eyeshields, Gloves